Upcoming Conferences, Preliminary Study Results, Purchase Agreements, Acquisitions, and Innovative Technologies - Analyst Notes on Intuitive Surgical, St. Jude Medical, Varian, Volcano and Masimo

NEW YORK, May 30, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Intuitive Surgical, Inc. (NASDAQ: ISRG), St. Jude Medical Inc. (NYSE: STJ), Varian Medical Systems Inc. (NYSE: VAR), Volcano Corporation (NASDAQ: VOLC) and Masimo Corporation (NASDAQ: MASI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3113-100free.

--
Intuitive Surgical, Inc. Analyst Notes
Intuitive Surgical, Inc. (Intuitive Surgical) posted on their events page that it will be making an attendance at the Goldman Sachs Healthcare Conference which will be held on June 11, 2014 at Los Angeles, California, US. The event is scheduled to begin at 10:40 a.m. PT. Additional information/updates regarding the said event will be made available through Intuitive Surgical's website. The full analyst notes on Intuitive Surgical are available to download free of charge at:

http://www.analystsreview.com/ISRG.pdf/Register

--
St. Jude Medical Inc. Analyst Notes
On May 22, 2014, St. Jude Medical Inc. (St. Jude Medical) announced preliminary results from the EnligHTN III Study, an international, non-randomized clinical trial. Results showed that the second-generation EnligHTN™ renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure. "St. Jude Medical is encouraged by the positive clinical results we're seeing from our renal denervation studies," said Dr. Mark D. Carlson, CMO for St. Jude Medical. "We have a long history of advancements in ablation technologies and have used our internal product development capabilities to optimize our multi-electrode renal denervation technology. We believe this therapy has the potential to dramatically improve the lives of millions of patients with severe high blood pressure and will continue to invest in renal denervation as a potential long-term growth driver." The full analyst notes on St. Jude Medical are available to download free of charge at:

http://www.analystsreview.com/STJ.pdf/Register

--
Varian Medical Systems Inc. Analyst Notes
On May 27, 2014, Varian Medical Systems Inc. (Varian) announced that it has signed a purchase agreement with YoungLin Healthcare Foundation, under which the Company will provide ProBeam® proton therapy system for deployment at the National Taiwan University in Taipei. Varian said that as per the agreement, it will provide the technology to equip three treatment rooms, two with gantries that rotate around the patient and one as a fixed-beam room. In addition to the ProBeam system, Varian will provide its ARIA® information management and Eclipse™ treatment planning software products. The agreement is valued at approximately $100 million including long-term operations and maintenance services. The Company expects to book the equipment portion of this order during FY 2014 while equipment installation is expected to take place in mid-2017, with patient treatments expected to begin in H2 2018. The full analyst notes on Varian are available to download free of charge at:

http://www.analystsreview.com/VAR.pdf/Register

--
Volcano Corporation Analyst Notes
On May 27, 2014, Volcano Corp. (Volcano) announced that it has signed an agreement for the acquisition of AtheroMed, Inc., a privately-held company that has developed the Phoenix® Atherectomy System used in the treatment of peripheral artery disease (PAD). Under the terms of the agreement, Volcano will make a payment of $115.0 million in cash at closing; plus a $15 million milestone payment if a Phoenix device currently before the FDA receives clearance by November 15, 2014. Scott Huennekens, President and CEO said, "We believe the potential of Phoenix to both grow the atherectomy market and achieve a strong market share position will facilitate our revenue, gross margin and operating income expansion goals." The Company expects the transaction to close in the current quarter. The full analyst notes on Volcano are available to download free of charge at:

http://www.analystsreview.com/VOLC.pdf/Register

--
Masimo Corporation Analyst Notes
On May 21, 2014, Masimo Corp. (Masimo) reported that the Centers for Medicare & Medicaid Services (CMS) has issued an updated guidance for hospital medication administration which will be made effective immediately. The updated guidance, which "strongly encouraged" hospitals to review best practices from safety organizations, aims to reduce preventable deaths or serious adverse events related to intravenous (IV) opioid medications and blood transfusions. The Company introduced the Masimo Patient SafetyNet™ which has been clinically shown to reduce preventable and costly rescue events, transfers to intensive care units, and deaths related to opioid-induced respiratory depression. "Masimo's noninvasive and continuous monitoring technologies have been shown to help clinicians safely and effectively monitor patients in the OR and medical-surgical floors," said Dr. Steve Barker, M.D., Ph.D., Chairman of the Scientific Advisory Board of Masimo. "Patient SafetyNet and SpHb, in particular, can equip caregivers with the right tools to meet new CMS guidance to improve patient safety and outcomes, while also reducing the cost of care." The full analyst notes on Masimo are available to download free of charge at:

http://www.analystsreview.com/MASI.pdf/Register

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review